Background: The THERAFLEX UV-Platelets system uses shortwave ultraviolet C light (UVC, 254 nm) to inactivate pathogens in platelet components. Plasma carryover influences pathogen inactivation and platelet quality following treatment. The plasma carryover in the standard platelets produced by our institution are below the intended specification (<30%). Methods: A pool and split study was carried out comparing untreated and UVC-treated platelets with <30% plasma carryover (n = 10 pairs). This data was compared to components that met specifications (>30% plasma). The platelets were tested over storage for in vitro quality. Results: Platelet metabolism was accelerated following UVC treatment, as demonstrated by increased glucose consumption and lactate production. UVC treatment caused increased externalization of phosphatidylserine on platelets and microparticles, activation of the GPIIb/IIIa receptor (PAC-1 binding), and reduced hypotonic shock response. Platelet function, as measured with thrombelastogram, was not affected by UVC treatment. Components with <30% plasma were similar to those meeting specification with the exception of enhanced glycolytic metabolism. Conclusion: This in vitro analysis demonstrates that treatment of platelets with <30% plasma carryover with the THERAFLEX UV-Platelets system affects some aspects of platelet metabolism and activation, although in vitro platelet function was not negatively impacted. This study also provides evidence that the treatment specifications of plasma carryover could be extended to below 30%.

1.
Schlenke P: Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother 2014;41:309-325.
2.
Chin S, Williams B, Gottlieb P, Margolis-Nunno H, Ben-Hur E, Hamman J, Jin R, Dubovi E, Horowitz B: Virucidal short wavelength ultraviolet light treatment of plasma and factor viii concentrate: protection of proteins by antioxidants. Blood 1995;86:4331-4336.
3.
Gomes AA, Silva-Junior AC, Oliveira EB, Asad LM, Reis NC, Felzenszwalb I, Kovary K, Asad NR: Reactive oxygen species mediate lethality induced by far-UV in Escherichia coli cells. Redox Rep 2005;10:91-95.
4.
Mohr H, Steil L, Gravemann U, Thiele T, Hammer E, Greinacher A, Muller TH, Volker U: A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009;49:2612-2624.
5.
Bashir S, Cookson P, Wiltshire M, Hawkins L, Sonoda L, Thomas S, Seltsam A, Tolksdorf F, Williamson LM, Cardigan R: Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets. Transfusion 2013;53:990-1000.
6.
Mohr H, Gravemann U, Bayer A, Muller TH: Sterilization of platelet concentrates at production scale by irradiation with short-wave ultraviolet light. Transfusion 2009;49:1956-1963.
7.
Sandgren P, Tolksdorf F, Struff WG, Gulliksson H: In-vitro quality of platelet concentrates treated with short-wave ultraviolet light. Transfusion 2010;50 (suppl):66A.
8.
Tynngard N, Trinks M, Berlin G: In vitro function of platelets treated with ultraviolet C light for pathogen inactivation: a comparative study with nonirradiated and gamma-irradiated platelets. Transfusion 2015;55:1169-1177.
9.
Johnson L, Loh YS, Kwok M, Marks DC: In vitro assessment of buffy-coat derived platelet components suspended in SSP+ treated with the Intercept Blood System. Transfus Med 2013;23:121-129.
10.
Picker SM, Oustianskaia L, Schneider V, Gathof BS: Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction. Vox Sang 2009;97:26-33.
11.
Johnson L, Winter KM, Reid S, Hartkopf-Theis T, Marschner S, Goodrich RP, Marks DC: The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sang 2011;101:208-214.
12.
Thiele T, Pohler P, Kohlmann T, Sümnig A, Aurich K, Selleng K, Westphal A, Bakchoul T, Petersmann A, Müller TH, Greinacher A, Seltsam A: Tolerance of platelet concentrates treated with UVC-light only for pathogen reduction - a phase I clinical trial. Vox Sang 2015;109:44-51.
13.
Johnson L, Coorey CP, Marks DC: The hemostatic activity of cryopreserved platelets is mediated by phosphatidylserine-expressing platelets and platelet microparticles. Transfusion 2014;54:1917-1926.
14.
Seghatchian J, Tolksdorf F: Characteristics of the THERAFLEX UV-platelets pathogen inactivation system - an update. Transfus Apher Sci 2012;46:221-229.
15.
Johnson L, Winter KM, Hartkopf-Theis T, Reid S, Kwok M, Marks DC: Evaluation of the automated collection and extended storage of apheresis platelets in additive solution. Transfusion 2012;52:503-509.
16.
Seltsam A, Muller TH: UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011;38:43-54.
17.
Sandgren P, Tolksdorf F, Struff WG, Gulliksson H: In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-platelets method. Vox Sang 2011;101:35-43.
18.
Dijkstra-Tiekstra MJ, Kuipers W, Setroikromo AC, Wildt-Eggen JD: Platelet capacity of various platelet pooling systems for buffy coat-derived platelet concentrates. Transfusion 2008;48:2114-2121.
19.
Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns Adu P: Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006;90:279-285.
20.
van der Meer PF, Kerkhoffs JL, Curvers J, Scharenberg J, de Korte D, Brand A, de Wildt-Eggen J: In vitro comparison of platelet storage in plasma and in four platelet additive solutions, and the effect of pathogen reduction: a proposal for an in vitro rating system. Vox Sang 2010;98:517-524.
21.
Holme S, Moroff G, Murphy S: A multi-laboratory evaluation of in vitro platelet assays: the tests for extent of shape change and response to hypotonic shock. Biomedical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion. Transfusion 1998;38:31-40.
22.
Verhaar R, Dekkers DW, De Cuyper IM, Ginsberg MH, de Korte D, Verhoeven AJ: UV-C irradiation disrupts platelet surface disulfide bonds and activates the platelet integrin alphaIIbbeta3. Blood 2008;112:4935-4939.
23.
Zhi L, Chi X, Vostal JG: In vitro and in vivo characterization of ultraviolet light C-irradiated human platelets in a 2 event mouse model of transfusion. PLoS One 2013;8:e79869.
24.
Van Aelst B, Devloo R, Vandekerckhove P, Compernolle V, Feys HB: Ultraviolet C light pathogen inactivation treatment of platelet concentrates preserves integrin activation but affects thrombus formation kinetics on collagen in vitro. Transfusion 2015;55:2404-2414.
25.
Keuren JF, Magdeleyns EJ, Govers-Riemslag JW, Lindhout T, Curvers J: Effects of storage-induced platelet microparticles on the initiation and propagation phase of blood coagulation. Br J Haematol 2006;134:307-313.
26.
Maslanka K, Uhrynowska M, Lopacz P, Wrobel A, Smolenska-Sym G, Guz K, Lachert E, Ostas A, Brojer E: Analysis of leucocyte antibodies, cytokines, lysophospholipids and cell microparticles in blood components implicated in post-transfusion reactions with dyspnoea. Vox Sang 2015;108:27-36.
27.
Pohler P, Muller M, Winkler C, Schaudien D, Sewald K, Muller TH, Seltsam A: Pathogen reduction by ultraviolet C light effectively inactivates human white blood cells in platelet products. Transfusion 2015;55:337-347.
28.
Castro E, Girones N, Guerrero N, Barea L, Fresno M: The effectiveness of UVC pathogen inactivation system on reducing the Trypanosoma cruzi and Leishmania infantum burden in platelets. Vox Sang 2008;95(suppl 1):290.
29.
Castro E, Gonzalez LM, Rubio JM, Ramiro R, Girones N, Montero E: The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets. Transfusion 2014;54:2207-2216.
30.
Steinmann E, Gravemann U, Friesland M, Doerrbecker J, Müller TH, Pietschmann T, Seltsam A: Two pathogen reduction technologies - methylene blue plus light and shortwave ultraviolet light - effectively inactivate hepatitis C virus in blood products. Transfusion 2013;53:1010-1018.
31.
Seed CR, Kiely P, Keller AJ: Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus. Intern Med J 2005;35:592-598.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.